Medicine
Relafen DS 1000 mg tablet
Relafen DS 1000 mg tablet is a prescription medicine containing Nabumetone for oral use, marketed by Carwin Pharmaceutical Associates, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Nabumetone
- Brand
- Relafen DS
- Strength
- 1000 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 30 tablets, 60 tablets
- Marketing authorisation holder
- Carwin Pharmaceutical Associates
- Manufacturer
- Carwin Pharmaceutical Associates
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- M01AX01 Nabumetone
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 September 2019
- Identifiers
- RxCUI 427726, 2200291DailyMed set ID a9a0af85-6c43-4a2d-ba75-0be4ca64c931NDC 15370-170Application ANDA203166
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle, plastic | 15370-170-10 | Carwin Pharmaceutical Associates | 12 May 2022 |
| 30 tablet in 1 bottle, plastic | 15370-170-30 | Carwin Pharmaceutical Associates | 20 September 2019 |
| 60 tablet in 1 bottle, plastic | 15370-170-60 | Carwin Pharmaceutical Associates | 28 February 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 24 December 1991 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Nabumetone 1000 mg tablet.
Other strengths and forms of Nabumetone
Clinical summary
Nabumetone is a nonsteroidal anti-inflammatory drug indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. It is available as tablets for oral use. MedsAcross supplies Nabumetone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NabumetoneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Nabumetone prescribing information (ANI Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Relafen DS 1000 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.